SCHEMBL29540482

SCHEMBL29540482

C[C@H](NC(=O)CNO)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.44
FAAH O00519 4/20 0.44
SLC6A5 Q9Y345 1/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPT P10636 1/20 0.43
MME P08473 3/20 0.41
ACE P12821 1/20 0.41
CPA1 P15085 1/20 0.41
ACE2 Q9BYF1 1/20 0.41
KDM4E B2RXH2 2/20 0.41
TSHR P16473 1/20 0.40
LTA4H P09960 2/20 0.38
ANPEP P15144 1/20 0.38
ECE1 P42892 1/20 0.38
HSD17B10 Q99714 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15123451 0.82 SMN1; SMN2 (0.44) SMN1; SMN2FAAHSLC6A5ALDH1A1MAPT
SCHEMBL15123452 0.82 SMN1; SMN2 (0.44) SMN1; SMN2FAAHSLC6A5ALDH1A1MAPT
SCHEMBL964581 0.81 SMN1; SMN2 (0.47) SMN1; SMN2FAAHSLC6A5ALDH1A1MAPT
SCHEMBL30628704 0.81 SMN1; SMN2 (0.47) SMN1; SMN2FAAHSLC6A5ALDH1A1MAPT
SCHEMBL26105356 0.78 SMN1; SMN2 (0.42) SMN1; SMN2FAAHSLC6A5ALDH1A1MAPT
SCHEMBL26105361 0.78 SMN1; SMN2 (0.42) SMN1; SMN2FAAHSLC6A5ALDH1A1MAPT
SCHEMBL23894144 0.77 PSMB5 (0.53) SMN1; SMN2FAAHSLC6A5ALDH1A1MAPT
SCHEMBL24764542 0.77 MME (0.42) SMN1; SMN2FAAHSLC6A5ALDH1A1MAPT
SCHEMBL10076082 0.76 ALDH1A1 (0.50) SMN1; SMN2FAAHSLC6A5ALDH1A1MAPT
SCHEMBL4811341 0.76 SMN1; SMN2 (0.47) SMN1; SMN2FAAHSLC6A5ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12415835-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-16 US disclosed
US-11891457-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-06 US disclosed
EP-3974563-A1 CYCLIC PEPTIDES Chugai Seiyaku Kabushiki Kaisha (JP) 2022-03-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891457-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R SMN1; SMN2 4620/4885FAAH 3575/4885SLC6A5 3991/4885
US-12415835-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R SMN1; SMN2 4620/4885FAAH 3575/4885SLC6A5 3991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.